FDA warned ABR Laboratory, a contract drug testing lab, that unverified microbial test methods and missed investigations made tested drugs adulterated.
What happened
FDA inspected ABR Laboratory, a contract testing laboratory in Hollywood, FL, from September 9 to 13, 2024. FDA found that ABR's microbial test method for over-the-counter (OTC) drug products was not shown to be equivalent to or better than the United States Pharmacopeia (USP) method and that method suitability was not performed for certain products, including a children’s product. FDA also found that ABR did not investigate out-of-range temperature and humidity readings, including a 2–8°C refrigerator that reached 17.4°C for more than 24 hours while holding reference microorganisms.
What FDA found
ABR did not establish and document that its microbial test method was accurate, sensitive, specific, and reproducible; the method was not verified as equivalent to or better than the USP method.
21 CFR 211.165(e)ABR did not perform method suitability testing for certain OTC drug products, including a children’s product.
21 CFR 211.165(e)ABR did not investigate out-of-range temperature and humidity readings, including a refrigerator holding reference microorganisms that was above its 2–8°C range for more than 24 hours and reached 17.4°C.
21 CFR 211.192
What FDA wants
FDA tells ABR to correct the violations promptly and to send FDA’s drug center (CDER) an independent assessment of its laboratory and investigation systems, a retrospective review with re-testing and customer notification plans, updated method-suitability procedures, and training records. The letter does not state a specific response deadline.
Who should pay attention
- drug companies that use ABR as a contract testing lab
- brands selling OTC drugs tested by ABR
- quality teams relying on contract lab microbial results
This is a summary. Read the original letter on fda.gov.